SSRIs and SNRIs in pregnancy

Following a review of epidemiological data, the MHRA has issued advice on the use of SSRIs and SNRIs in pregnancy taking into account the increased risk of persistent pulmonary hypertension in the newborn (PPHN), particularly in later stages of pregnancy.

The advice states that healthcare professionals, including midwives, should be aware of the increased risk of PPHN: the observed increase in risk is about 3 to 4 extra cases per 1000 patients. Enquiry about the use of these medicines, especially in later stages of pregnancy, is encouraged and close observation of neonates exposed to the two classes of agents is recommended after birth.

View MHRA Drug Safety Update

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more